Atopic Dermatitis - Pipeline Review, H2 2016

Published: Aug, 2016 | Pages: 375 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Atopic Dermatitis - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Atopic Dermatitis - Pipeline Review, H2 2016', provides an overview of the Atopic Dermatitis pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Atopic Dermatitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Atopic Dermatitis and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Atopic Dermatitis
- The report reviews pipeline therapeutics for Atopic Dermatitis by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Atopic Dermatitis therapeutics and enlists all their major and minor projects
- The report assesses Atopic Dermatitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Atopic Dermatitis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Atopic Dermatitis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Atopic Dermatitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2
List of Tables 8
List of Figures 11
Introduction 12
Global Markets Direct Report Coverage 12
Atopic Dermatitis Overview 13
Therapeutics Development 14
Pipeline Products for Atopic Dermatitis - Overview 14
Pipeline Products for Atopic Dermatitis - Comparative Analysis 15
Atopic Dermatitis - Therapeutics under Development by Companies 16
Atopic Dermatitis - Therapeutics under Investigation by Universities/Institutes 22
Atopic Dermatitis - Pipeline Products Glance 23
Late Stage Products 23
Clinical Stage Products 24
Early Stage Products 25
Unknown Stage Products 26
Atopic Dermatitis - Products under Development by Companies 27
Atopic Dermatitis - Products under Investigation by Universities/Institutes 35
Atopic Dermatitis - Companies Involved in Therapeutics Development 36
AbbVie Inc 36
Accolade Pharmaceuticals, LLC 37
AlbireoPharma 38
Almirall, S.A. 39
Amgen Inc. 40
Amorepacific Corporation 41
Anacor Pharmaceuticals, Inc. 42
AnaMar AB 43
AnaptysBio, Inc. 44
AnGes MG, Inc. 45
arGEN-X BV 46
Avexxin AS 47
Blueberry Therapeutics Ltd 48
Brickell Biotech, Inc. 49
Celgene Corporation 50
Cell Medica Limited 51
Cellceutix Corporation 52
ChemoCentryx, Inc. 53
ChironWells GmbH 54
Chugai Pharmaceutical Co., Ltd. 55
Creabilis SA 56
Curapel Limited 57
Dermala Inc 58
Dr. August Wolff GmbH & Co. KG Arzneimittle 59
Eli Lilly and Company 60
F. Hoffmann-La Roche Ltd. 61
Foamix Pharmaceuticals Ltd. 62
Fountain Biopharma Inc. 63
Galapagos NV 64
GlaxoSmithKline Plc 65
Glenmark Pharmaceuticals Ltd. 66
Grupo Ferrer Internacional, S.A. 67
Han Wha Pharma Co., Ltd. 68
HanAll Biopharma Co., Ltd. 69
Heptares Therapeutics Limited 70
Herantis Pharma Plc 71
iCo Therapeutics Inc. 72
Immune Pharmaceuticals Inc. 73
Inflamalps SA 74
Japan Tobacco Inc. 75
Johnson & Johnson 76
Kang Stem Biotech Co., Ltd. 77
KPI Therapeutics, Inc. 78
LegoChem Biosciences, Inc 79
LEO Pharma A/S 80
Madam Therapeutics B.V. 81
MedImmune, LLC 82
NeoPharm Co., Ltd. 83
Nippon Shinyaku Co., Ltd. 84
Novan, Inc. 85
Novartis AG 86
Orbis Biosciences Inc 87
Otsuka Holdings Co., Ltd. 88
Oxagen Limited 89
Pfizer Inc. 90
Pharis Biotec GmbH 91
Pharmedartis GmbH 92
Provectus Biopharmaceuticals, Inc. 93
PuriCore Plc 94
Quorum Innovations LLC 95
Regeneron Pharmaceuticals Inc 96
Signum Dermalogix, Inc 97
Spherium Biomed S.L. 98
sterna biologicals Gmbh & Co KG 99
Sucampo Pharmaceuticals, Inc. 100
Sun Pharma Advanced Research Company Ltd. 101
SWITCH Biotech LLC 102
Takeda Pharmaceutical Company Limited 103
Thesan Pharmaceuticals, Inc. 104
Tioga Pharmaceuticals, Inc. 105
Torrent Pharmaceuticals Limited 106
Valeant Pharmaceuticals International, Inc. 107
Vicore Pharma AB 108
Vitae Pharmaceuticals, Inc. 109
VivaCell Biotechnology Espana S.L. 110
Xencor, Inc. 111
Ziarco Pharma Ltd 112
Atopic Dermatitis - Therapeutics Assessment 113
Assessment by Monotherapy Products 113
Assessment by Target 114
Assessment by Mechanism of Action 119
Assessment by Route of Administration 124
Assessment by Molecule Type 126
Drug Profiles 128
A-3914 - Drug Profile 128
A-5425 - Drug Profile 129
AKP-11 - Drug Profile 130
Allergen for House Dust Mite Induced Atopic Dermatitis - Drug Profile 132
ALX-101 - Drug Profile 133
AM-1030 - Drug Profile 134
AMG-0101 - Drug Profile 135
Anatabine - Drug Profile 137
ANB-020 - Drug Profile 140
apremilast - Drug Profile 142
Aptamers to Inhibit Galectin-3 for Atopic Dermatitis - Drug Profile 153
ARGX-112 - Drug Profile 154
ARN-077 - Drug Profile 155
asimadoline - Drug Profile 156
AVX-001 - Drug Profile 158
B-244 - Drug Profile 159
baricitinib - Drug Profile 160
BB-2702 - Drug Profile 167
BBI-2000 - Drug Profile 168
BBI-5000 - Drug Profile 169
bertilimumab - Drug Profile 170
betamethasone valerate - Drug Profile 174
Biologic for Atopic Dermatitis and Eczema - Drug Profile 175
brilacidin tetrahydrochloride - Drug Profile 176
BTX-1204 - Drug Profile 185
C-21 - Drug Profile 186
CBP-174 - Drug Profile 188
CBP-201 - Drug Profile 189
CCX-6239 - Drug Profile 190
CDE-001 - Drug Profile 191
Cis-Urocanic Acid - Drug Profile 192
cobamamide - Drug Profile 195
crisaborole - Drug Profile 196
CT-101 - Drug Profile 201
CT-103 - Drug Profile 202
CT-327 - Drug Profile 203
CT-340 - Drug Profile 206
cyclosporine - Drug Profile 207
dalazatide - Drug Profile 208
DMT-210 - Drug Profile 213
Drug for Atopic Dermatitis - Drug Profile 214
dupilumab - Drug Profile 215
FB-825 - Drug Profile 221
fevipiprant - Drug Profile 222
FIB-116 - Drug Profile 224
Furestem-AD - Drug Profile 225
GBR-830 - Drug Profile 226
GLPG-2534 - Drug Profile 227
GSK-3772847A - Drug Profile 228
Histimex - Drug Profile 229
HS-378 - Drug Profile 230
IDP-124 - Drug Profile 231
JTE-052 - Drug Profile 232
KPI-150 - Drug Profile 233
LCB-030110 - Drug Profile 234
lebrikizumab - Drug Profile 235
LEKTI-6 - Drug Profile 238
LEO-32731 - Drug Profile 239
LEO-39652 - Drug Profile 240
MEDI-9314 - Drug Profile 241
mepolizumab - Drug Profile 242
MLR-1130 - Drug Profile 247
mometasone furoate - Drug Profile 248
Monoclonal Antibody to Antagonize PAR-2 for Atopic Dermatitis and Inflammation - Drug Profile 249
Monoclonal Antibody to Inhibit IL-4 and IL-13 for Atopic Dermatitis - Drug Profile 250
Monoclonal Antibody to Target Th22 cell/IL-22 pathway for Inflammatory Bowel Diseases, Atopic Dermatitis and Colorectal Cancer - Drug Profile 251
N-oleoylethanolamine - Drug Profile 252
nemolizumab - Drug Profile 253
NPH-12 - Drug Profile 254
NS-141 - Drug Profile 255
OC-000459 - Drug Profile 256
OC-2417 - Drug Profile 258
octenidine hydrochloride - Drug Profile 259
OLX-103 - Drug Profile 260
omiganan pentahydrochloride - Drug Profile 261
OPA-15406 - Drug Profile 263
P-10 - Drug Profile 265
P-148 - Drug Profile 266
PAC-14028 - Drug Profile 267
Peptide to Antagonize CX3CR1 for Atopic Dermatitis - Drug Profile 269
Peptides to Antagonize TNFR-1 for Atopic Dermatitis - Drug Profile 270
PF-04965842 - Drug Profile 271
PH-10 - Drug Profile 272
PL-601 - Drug Profile 275
PMA-101R - Drug Profile 276
PMA-201 - Drug Profile 277
PMA-411R - Drug Profile 278
PR-022 - Drug Profile 279
prednisone - Drug Profile 280
PZ-235 - Drug Profile 281
Q-301 - Drug Profile 282
Qi-507 - Drug Profile 283
roflumilast - Drug Profile 284
RTU-1096 - Drug Profile 289
RVT-501 - Drug Profile 291
SB-011 - Drug Profile 292
SB-414 - Drug Profile 293
secukinumab - Drug Profile 294
SIG-1311 - Drug Profile 307
SIG-1322 - Drug Profile 308
Small Molecule for Atopic Dermatitis - Drug Profile 309
Small Molecule to Modulate S1PR1 for Atopic Dermatitis - Drug Profile 310
Small Molecules for Atopic Dermatitis - Drug Profile 311
Small Molecules for Atopic Dermatitis - Drug Profile 312
Small Molecules to Antagonize TNFR-1 for Atopic Dermatitis - Drug Profile 313
SP-14019 - Drug Profile 314
SUN-0597 - Drug Profile 315
SWT-01113 - Drug Profile 317
SWT-05141 - Drug Profile 318
Synthetic Peptides to Inhibit Kallikrein for Immunology, Dermatological and Genetic Disorders - Drug Profile 319
tacrolimus - Drug Profile 320
tezepelumab - Drug Profile 321
tralokinumab - Drug Profile 323
upadacitinib tartrate - Drug Profile 325
ustekinumab - Drug Profile 327
VTP-38543 - Drug Profile 333
WBI-1001 - Drug Profile 334
WOL-071007 - Drug Profile 336
XmAb-7195 - Drug Profile 337
YJC-10592 - Drug Profile 338
Zafi-1 - Drug Profile 339
ZPL-389 - Drug Profile 340
ZPL-521 - Drug Profile 342
Atopic Dermatitis - Dormant Projects 343
Atopic Dermatitis - Discontinued Products 353
Atopic Dermatitis - Product Development Milestones 355
Featured News & Press Releases 355
Appendix 365
Methodology 365
Coverage 365
Secondary Research 365
Primary Research 365
Expert Panel Validation 365
Contact Us 365
Disclaimer 366

List of Tables

Number of Products under Development for Atopic Dermatitis, H2 2016 23
Number of Products under Development for Atopic Dermatitis - Comparative Analysis, H2 2016 24
Number of Products under Development by Companies, H2 2016 25
Number of Products under Development by Companies, H2 2016 (Contd..1) 26
Number of Products under Development by Companies, H2 2016 (Contd..2) 27
Number of Products under Development by Companies, H2 2016 (Contd..3) 28
Number of Products under Development by Companies, H2 2016 (Contd..4) 29
Number of Products under Development by Companies, H2 2016 (Contd..5) 30
Number of Products under Investigation by Universities/Institutes, H2 2016 31
Comparative Analysis by Late Stage Development, H2 2016 32
Comparative Analysis by Clinical Stage Development, H2 2016 33
Comparative Analysis by Early Stage Development, H2 2016 34
Comparative Analysis by Unknown Stage Development, H2 2016 35
Products under Development by Companies, H2 2016 36
Products under Development by Companies, H2 2016 (Contd..1) 37
Products under Development by Companies, H2 2016 (Contd..2) 38
Products under Development by Companies, H2 2016 (Contd..3) 39
Products under Development by Companies, H2 2016 (Contd..4) 40
Products under Development by Companies, H2 2016 (Contd..5) 41
Products under Development by Companies, H2 2016 (Contd..6) 42
Products under Development by Companies, H2 2016 (Contd..7) 43
Products under Investigation by Universities/Institutes, H2 2016 44
Atopic Dermatitis - Pipeline by AbbVie Inc, H2 2016 45
Atopic Dermatitis - Pipeline by Accolade Pharmaceuticals, LLC, H2 2016 46
Atopic Dermatitis - Pipeline by AlbireoPharma, H2 2016 47
Atopic Dermatitis - Pipeline by Almirall, S.A., H2 2016 48
Atopic Dermatitis - Pipeline by Amgen Inc., H2 2016 49
Atopic Dermatitis - Pipeline by Amorepacific Corporation, H2 2016 50
Atopic Dermatitis - Pipeline by Anacor Pharmaceuticals, Inc., H2 2016 51
Atopic Dermatitis - Pipeline by AnaMar AB, H2 2016 52
Atopic Dermatitis - Pipeline by AnaptysBio, Inc., H2 2016 53
Atopic Dermatitis - Pipeline by AnGes MG, Inc., H2 2016 54
Atopic Dermatitis - Pipeline by arGEN-X BV, H2 2016 55
Atopic Dermatitis - Pipeline by Avexxin AS, H2 2016 56
Atopic Dermatitis - Pipeline by Blueberry Therapeutics Ltd, H2 2016 57
Atopic Dermatitis - Pipeline by Brickell Biotech, Inc., H2 2016 58
Atopic Dermatitis - Pipeline by Celgene Corporation, H2 2016 59
Atopic Dermatitis - Pipeline by Cell Medica Limited, H2 2016 60
Atopic Dermatitis - Pipeline by Cellceutix Corporation, H2 2016 61
Atopic Dermatitis - Pipeline by ChemoCentryx, Inc., H2 2016 62
Atopic Dermatitis - Pipeline by ChironWells GmbH, H2 2016 63
Atopic Dermatitis - Pipeline by Chugai Pharmaceutical Co., Ltd., H2 2016 64
Atopic Dermatitis - Pipeline by Creabilis SA, H2 2016 65
Atopic Dermatitis - Pipeline by Curapel Limited, H2 2016 66
Atopic Dermatitis - Pipeline by Dermala Inc, H2 2016 67
Atopic Dermatitis - Pipeline by Dr. August Wolff GmbH & Co. KG Arzneimittle, H2 2016 68
Atopic Dermatitis - Pipeline by Eli Lilly and Company, H2 2016 69
Atopic Dermatitis - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 70
Atopic Dermatitis - Pipeline by Foamix Pharmaceuticals Ltd., H2 2016 71
Atopic Dermatitis - Pipeline by Fountain Biopharma Inc., H2 2016 72
Atopic Dermatitis - Pipeline by Galapagos NV, H2 2016 73
Atopic Dermatitis - Pipeline by GlaxoSmithKline Plc, H2 2016 74
Atopic Dermatitis - Pipeline by Glenmark Pharmaceuticals Ltd., H2 2016 75
Atopic Dermatitis - Pipeline by Grupo Ferrer Internacional, S.A., H2 2016 76
Atopic Dermatitis - Pipeline by Han Wha Pharma Co., Ltd., H2 2016 77
Atopic Dermatitis - Pipeline by HanAll Biopharma Co., Ltd., H2 2016 78
Atopic Dermatitis - Pipeline by Heptares Therapeutics Limited, H2 2016 79
Atopic Dermatitis - Pipeline by Herantis Pharma Plc, H2 2016 80
Atopic Dermatitis - Pipeline by iCo Therapeutics Inc., H2 2016 81
Atopic Dermatitis - Pipeline by Immune Pharmaceuticals Inc., H2 2016 82
Atopic Dermatitis - Pipeline by Inflamalps SA, H2 2016 83
Atopic Dermatitis - Pipeline by Japan Tobacco Inc., H2 2016 84
Atopic Dermatitis - Pipeline by Johnson & Johnson, H2 2016 85
Atopic Dermatitis - Pipeline by Kang Stem Biotech Co., Ltd., H2 2016 86
Atopic Dermatitis - Pipeline by KPI Therapeutics, Inc., H2 2016 87
Atopic Dermatitis - Pipeline by LegoChem Biosciences, Inc, H2 2016 88
Atopic Dermatitis - Pipeline by LEO Pharma A/S, H2 2016 89
Atopic Dermatitis - Pipeline by Madam Therapeutics B.V., H2 2016 90
Atopic Dermatitis - Pipeline by MedImmune, LLC, H2 2016 91
Atopic Dermatitis - Pipeline by NeoPharm Co., Ltd., H2 2016 92
Atopic Dermatitis - Pipeline by Nippon Shinyaku Co., Ltd., H2 2016 93
Atopic Dermatitis - Pipeline by Novan, Inc., H2 2016 94
Atopic Dermatitis - Pipeline by Novartis AG, H2 2016 95
Atopic Dermatitis - Pipeline by Orbis Biosciences Inc, H2 2016 96
Atopic Dermatitis - Pipeline by Otsuka Holdings Co., Ltd., H2 2016 97
Atopic Dermatitis - Pipeline by Oxagen Limited, H2 2016 98
Atopic Dermatitis - Pipeline by Pfizer Inc., H2 2016 99
Atopic Dermatitis - Pipeline by Pharis Biotec GmbH, H2 2016 100
Atopic Dermatitis - Pipeline by Pharmedartis GmbH, H2 2016 101
Atopic Dermatitis - Pipeline by Provectus Biopharmaceuticals, Inc., H2 2016 102
Atopic Dermatitis - Pipeline by PuriCore Plc, H2 2016 103
Atopic Dermatitis - Pipeline by Quorum Innovations LLC, H2 2016 104
Atopic Dermatitis - Pipeline by Regeneron Pharmaceuticals Inc, H2 2016 105
Atopic Dermatitis - Pipeline by Signum Dermalogix, Inc, H2 2016 106
Atopic Dermatitis - Pipeline by Spherium Biomed S.L., H2 2016 107
Atopic Dermatitis - Pipeline by sterna biologicals Gmbh & Co KG, H2 2016 108
Atopic Dermatitis - Pipeline by Sucampo Pharmaceuticals, Inc., H2 2016 109
Atopic Dermatitis - Pipeline by Sun Pharma Advanced Research Company Ltd., H2 2016 110
Atopic Dermatitis - Pipeline by SWITCH Biotech LLC, H2 2016 111
Atopic Dermatitis - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 112
Atopic Dermatitis - Pipeline by Thesan Pharmaceuticals, Inc., H2 2016 113
Atopic Dermatitis - Pipeline by Tioga Pharmaceuticals, Inc., H2 2016 114
Atopic Dermatitis - Pipeline by Torrent Pharmaceuticals Limited, H2 2016 115
Atopic Dermatitis - Pipeline by Valeant Pharmaceuticals International, Inc., H2 2016 116
Atopic Dermatitis - Pipeline by Vicore Pharma AB, H2 2016 117
Atopic Dermatitis - Pipeline by Vitae Pharmaceuticals, Inc., H2 2016 118
Atopic Dermatitis - Pipeline by VivaCell Biotechnology Espana S.L., H2 2016 119
Atopic Dermatitis - Pipeline by Xencor, Inc., H2 2016 120
Atopic Dermatitis - Pipeline by Ziarco Pharma Ltd, H2 2016 121
Assessment by Monotherapy Products, H2 2016 122
Number of Products by Stage and Target, H2 2016 124
Number of Products by Stage and Mechanism of Action, H2 2016 129
Number of Products by Stage and Route of Administration, H2 2016 134
Number of Products by Stage and Molecule Type, H2 2016 136
Atopic Dermatitis - Dormant Projects, H2 2016 352
Atopic Dermatitis - Dormant Projects (Contd..1), H2 2016 353
Atopic Dermatitis - Dormant Projects (Contd..2), H2 2016 354
Atopic Dermatitis - Dormant Projects (Contd..3), H2 2016 355
Atopic Dermatitis - Dormant Projects (Contd..4), H2 2016 356
Atopic Dermatitis - Dormant Projects (Contd..5), H2 2016 357
Atopic Dermatitis - Dormant Projects (Contd..6), H2 2016 358
Atopic Dermatitis - Dormant Projects (Contd..7), H2 2016 359
Atopic Dermatitis - Dormant Projects (Contd..8), H2 2016 360
Atopic Dermatitis - Dormant Projects (Contd..9), H2 2016 361
Atopic Dermatitis - Discontinued Products, H2 2016 362
Atopic Dermatitis - Discontinued Products (Contd..1), H2 2016 363